Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 2007

View Archived Issues

Promising preclinical activity of new plant-produced vaccine candidates at Integrated

Anti-Abeta fusion antibody successfully delivered to the brain through a molecular Trojan horse

Recent patents impart new therapeutic agents for cancer

Recent patents disclose new therapeutic agents for anxiety, depression and sleep disorders

Snapshots: Preclinical studies of agents under development for schizophrenia

Snapshots of studies of isavuconazole activity

Senetek initiates clinical trials of Pyratine 6 for acne rosacea

Alpha-lipoic acid studied for prevention of chemotherapy-induced neuropathy

HuMax-EGFr studied with chemoradiation for NSCLC

New phase II trial studies EndoTAG-1 for triple receptor negative breast cancer

MEK inhibitor ARRY-704 begins phase I trial in cancer patients

Positive topline phase II results for DX-88 in hereditary angioedema

Hadasit and Yissum jointly disclose novel antifungal agents in recent patent

Cardiac myosin activator CK-1827452 begins phase II development

Promacta studied in patients previously treated for chronic ITP

Merck licenses Coley's VaxImmune vaccine adjuvant

Japanese budget clearance for studies of H5N1 flu vaccine and Ampligen

Poniard begins phase I trial of oral picoplatin

Enrollment open in phase II study of A-002 for stable coronary artery disease

GSK presents new pan-Akt inhibitor at AACR meeting

PI-88 improves disease-free survival in liver cancer patients after surgery

ECE-1 as a novel target in breast cancer therapy

FDA Advisory Committee votes against recommending approval of Arcoxia

QBI-139, an EVade(TM) ribonuclease variant, proves safe in rodents

LB-80317 shows broad spectrum anti-HBV activity against resistant mutants in vitro

Phase I results reported at AACR meeting for brain-penetrating doxorubicin analogue

Good safety and pharmacokinetic profile for multiple-dose PTC-299 in humans

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...